ArticleScientific reports2025
Compound 48/80 increases bladder compliance by activating MMP-2 and inhibiting TIMP-2.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The urinary bladder must remain distensible enough to expand as urine is produced yet strong enough to expel urine without rupture. Disruption in the arrangement of the bladder wall extracellular matrix (ECM) can lead to alterations in mechanical compliance, disrupting normal function and resulting in bladder dysfunction. Previously, we discovered that the mast cell activator compound 48/80 increased detrusor excitability and bladder wall mechanical compliance, resulting in increased urination frequency in mice in a mast cell-independent manner. While the effects on detrusor excitability depended on urothelial prostaglandin production, the mechanisms by which compound 48/80 altered mechanical compliance remained unclear. This study tests the hypothesis that compound 48/80 increases compliance through activation of matrix metalloproteases (MMPs) in the bladder wall. Using the Pentaplanar Reflected Image Macroscopy (PRIM) System and multiphoton microscopy, we measured ex vivo intravesical pressure, mechanical compliance, wall thickness, and permeability in bladders from C57Bl/6 mice before and after exposure to compound 48/80. Intravesical instillation of compound 48/80 increased mechanical compliance and reduced wall thickness without affecting urothelial permeability. This change in compliance was inhibited by the nonspecific MMP inhibitor doxycycline and the MMP-2 inhibitor ARP100. Bladder MMP-2 activity increased, and TIMP-2 activity decreased, after incubation with compound 48/80 as measured by zymography. Together, these findings suggest that compound 48/80 changes bladder mechanical compliance through ECM breakdown caused by rapid activation of MMP-2 and inhibition of TIMP-2. Moreover, these effects occur without altering urothelial permeability, suggesting a novel receptor-mediated mechanism and not a direct effect of compound 48/80 on MMP-2 or TIMP-2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.